The DNA methylation market size is estimated to be USD 1528.5 million in 2022 and is expected to witness a CAGR of 14.88% during the forecast period 2023-2033. Rise in cancer diagnoses worldwide, reducing cost of therapy combined with the simplification of product approvals, and substantial direct government investment is expected to propel the market growth. Furthermore, availability of different test kits and rise in interest in research that is based on epigenetics is projected to support the market growth. However, high price of the technology and issues about a lack of technical knowledge is expected to hinder the growth.

Availability of different test kits is expected to propel the market growth during the projected period. The availability of different test kits has given market participants numerous opportunities. For instance, Boca ScientificInc. announced the introduction of MethylDetect DNA Methylation Assay Kits to their product lineup in June 2022. These features keep it being widely adopted by research institutions and other pharmaceutical and biotechnology companies.

Rise in interest in research that is based on epigenetics is predicted to fuel the market growth. For instance, Twist Bioscience introduced the NGS Methylation Detection System in February 2021. This system will be used to analyse liquid biopsy cancer and epigenetic studies. Epigenetics is the study of structural and functional changes to the genome that do not result from changes to the DNA sequence. These modifications affect gene expression without changing DNA sequences and are carried on to the daughter cells. The key epigenetic alterations that have received the most focus in recent years include methylation.

Segmentation

By Product

The market is categorized into kits & reagents, consumables, and instruments & software. In the global market, the consumables segment accounted for the largest revenue share in 2022 owing to the its widespread application in DNA sequencing processes and medical diagnosis. Fast turnaround times and high throughput output are two other major drivers of the expansion. The research sector employs a broad range of consumables, including tubes, vials, microarray panels, dispensers, and pipette tips. The market’s overall demand is continuing to increase due to the high volume needs for these consumables. PacBio announced an increase of their product line in April 2022 by introducing new DNA methylation consumables. All of its customers who use Sequel II and Sequel IIe systems have direct access to these. The growing need for protein-modifying and enzymes in the DNA methylation procedure is expected to fuel the lucrative growth of the enzyme market in the upcoming years.

By Technology

The market is divided into sequencing, polymerase chain reaction, microarray, and others. In 2022, the sequencing segment accounted for the highest revenue share due to rapid development of technologies that provide affordable, precise, and quick results. To comprehend the epigenetic landscape of immune-related diseases put on by tobacco use, researchers have used whole-genome bisulfite sequencing. The development of this technology in scientific studies to comprehend the harmful impacts of smoking and how it connects to diseases provides additional growth potential in the sector. PCR is expected to grow significant growth in the upcoming years due to rise in its application in diagnostics and DNA sequencing techniques. The introduction of EpiDirect, a qPCR-based test for detecting DNA methylation without pre-treatment, was announced by Pentabase A/S in May 2022.

By Application

The market is segregated into diagnostics, gene therapy, clinical research, and others. In the global market, the clinical research segment accounted for the largest revenue share in 2022 owing to increase in clinical trials for various disorders. More growth opportunities are also offered by rising R&D spending and demand for prospective biomarkers. According to a Springer paper from July 2020, disease-related methylation alterations could be employed as biomarkers at all stages of clinical disease management. These numerous stages range from early diagnosis and risk assessment screening to individualised patient management for chronic and relapsing disease. The diagnostic segment is predicted to grow the quickest in the upcoming years. DNA methylation profiling is a new technology that has the potential to improve pathological diagnosis precision.

By End Use

The market is segmented into research academia, pharmaceutical & biotechnology company, and hospital & diagnostic laboratories. In 2022, the pharmaceutical & biotechnology company segment accounted for the largest revenue share owing to expanding use of DNA methylation in the fields of molecular biology and genomics. Furthermore, prominent market players’ growing adoption of high throughput technologies as NGS also keeps new growth prospects open. Base Genomics stated in June 2020 that it would use TET-assisted pyridine borane sequencing (TAPS) technology created by the University of Oxford to identify cancer epigenetic markers in blood samples. The increasing R&D in the epigenetics field is expected to lead to significant growth in research and academia over the next few years. This continues to be a promising engine of growth, along with rising government financing assistance.In July 2022, a research in Genome Biology reported that DNA methylation in bacteria regulates pathogenicity, gene expression, and reproduction.

Regional Markets

In 2022, North America region accounted for the highest revenue in the DNA methylation market and is expected to maintain its dominance during the forecast period. This is attributed to the extensive network of R&D and manufacturing facilities, and rise in product launches and approvals. In addition, the rising demand for protein expression systems has greatly fuelled regional expansion. Twist Bioscience unveiled a human methylome panel in May 2022 to enable the detection of methylation fractions in a variety of applications. This encourages the discovery of differentially methylated regions and the identification of epigenetic targets for studies on cancer metastasis and human development. The development of a liquid biopsy diagnostic model for early breast cancer diagnosis was announced by AnchorDxentered in September 2020. This diagnostic paradigm focuses on circulating DNA-based methylation patterns that are independent of cells. Similar to this, Oncgnostics GmbH was granted permission by the Chinese government to offer its GynTect test to medical professionals and patients in August 2022.

Competitor Insights

Some of the key players operating in the DNA methylation market are Merck KGaA, Sysmex Corporation, Active Motif, Inc., Abcam plc., F. Hoffmann-La Roche Ltd., New England Biolabs Inc., Diagenode Diagnostics S.A., New England Biolabs, QIAGEN N.V., Thermo-Fisher Scientific Inc.,  Zymo Research Corporation, Agilent Technologies Inc., Exact Sciences Corporation, Illumina Inc., EpiGentek Group Inc., BioRad Laboratories Inc., Pacific Biosciences Inc., and PerkinElmer Inc.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, in order to expand the company’s liquid biopsy platforms and enhance patient cancer care, Foundation Medicine, Inc. acquired Lexent Bio, Inc. in June 2020. This cutting-edge method can be used to detect the development of cancer in a variety of patient populations.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product, technology, application, and end use from 2023 to 2033.

Report Scope:

Segmentation: DNA Methylation Market Report 2022 – 2033

Product (Revenue, USD Million), 2022 – 2033

• Kits & Reagents
• Consumables
• Instruments & Software

Technology (Revenue, USD Million), 2022 – 2033

• Sequencing
• Polymerase Chain Reaction
• Microarray
• Others

Application (Revenue, USD Million), 2022 – 2033

• Diagnostics
• Gene Therapy
• Clinical Research
• Others

End Use (Revenue, USD Million), 2022 – 2033

• Research Academia
• Pharmaceutical & Biotechnology Company
• Hospital & Diagnostic Laboratories

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA